Rethink Imaging

The episode delivers genuine clinical pearls—kidney lesion exoneration, bowel viability mapping, PE protocol failure elimination—but significant airtime is consumed by basic-level explanations of CT physics for a lay audience, the tangential AI self-congratulation segment, and the host's restaurant/photography analogies. The density is real but inconsistent.

“if we can confidently say there's no iodine content, no enhancement, no blood flow in that lesion, we can exonerate it as benign and never recommend a follow up imaging”

“we've used this technology to basically eliminate our failure rate on these scans”

The adoption-gap insight—that most facilities with dual energy scanners never actually use the capability—is a genuinely underappreciated and sharp observation, and the push for quantitative DICOM standards in PACs is a specific actionable angle. However, the bulk of the episode is standard educational content about dual energy and photon counting that would be familiar to anyone who attends radiology conferences.

“most places that install these scanners don't actually use it for these purposes. So we have an implementation and adoption challenge beyond just siting the scanner in the hospital”

“we're stuck going back to the manufacturer software, which I've already told you, nobody uses because we don't have the time”

Dr. Sodikson is a genuine practitioner-innovator: Division Chief of Emergency Radiology at Mass General Brigham, Harvard faculty, and the founder of CACTI, who actually installed one of the first clinical full-body photon counting scanners and has been building dual energy programs since 2013. His authority comes from doing the work, not from being a conference circuit thought leader.

“We put in our first dual energy scanner in the emergency room where I work at Brigham and Women's Hospital in 2013. That was my start and did a lot of work up front there”

“I've been needling the CT manufacturers for years on this”

The episode has useful concrete numbers—0.2mm ultra-high-resolution mode, 0.4mm standard mode versus prior 0.5–0.6mm, 30–50% dose reduction, nine-ER network, dual energy since 2013—but is missing published outcome data, failure-rate figures, or patient-volume context that would sharpen the evidence base considerably.

“our standard mode is 0.4 millimeters, our ultra high resolution mode is 0.2 millimeters”

“we can knock it down even further, you know, another 30%, maybe 50%, depending how aggressive you want to get”

The host pursues a couple of genuine clarifications (etymology of 'enhancement,' definition of septa) showing some curiosity, but the overall format is permission-granting monologue prompts with no real pushback on claims, no probing on cost-effectiveness or implementation failures, and a weak segment celebrating not mentioning AI that consumes time without adding substance.

“Can I ask about the etymology of the term enhancement as it applies here?”

“That is impressive and I appreciate it. And we are always talking about AI on this show. Our listeners know.”